Company: ARTL
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001640334-25-000825
Chunk: 114

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 114
---
s from disposition of marketable securities  -   1,750 Net cash provided by investing activities  -   1,269          CASH FLOWS FROM FINANCING ACTIVITIES        Proceeds from issuance of common shares for cash, net  -   55 Net cash provided by financing activities  -   55          Effect of exchange rate changes on cash  5   (2)         Net change in cash and cash equivalents  (1,592)  (1,620)Cash and cash equivalents - beginning of period  2,338   2,815 Cash and cash equivalents - end of period $746  $1,195          Supplemental Cash Flow Information        Cash paid for interest $-  $- Cash paid for income taxes $-  $-          NON-CASH FINANCING AND INVESTING ACTIVITIES:        Initial recognition of the right-of-use asset and lease liability $-  $111 

 6Table of Contents

ARTELO BIOSCIENCES, INC.

Notes to the Consolidated Financial Statements

(In thousands, except share and per share data)

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS ARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation incorporated on May 2, 2011, and based in San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America (“GAAP”), and the Company’s fiscal year end is December 31. The Company registered wholly owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016, and in the United Kingdom (“UK”), Trinity Research & Development Limited, on June 2, 2017. On January 8, 2020, Trinity Research and Development Limited changed its name to Artelo Biosciences Limited. The Company incorporated a wholly owned subsidiary in Canada, Artelo Biosciences Corporation, on March 18, 2020. Operations in the subsidiaries have been consolidated in the financial statements. The Company is a clinical stage biopharmaceutical company focused on developing therapeutics that target lipid-signaling pathways, including treatments intended to modulate the endocannabinoid system (the “ECS”), a family of receptors and